Semaglutide vs Tirzepatide: Comparing Weight Loss Medications
Struggling to choose between Semaglutide and Tirzepatide for weight loss? Here’s what you need to know:
- Tirzepatide (Zepbound™): Offers greater weight loss (15–22%) and better blood sugar control than Semaglutide. Works as a dual-action drug targeting both GLP-1 and GIP receptors.
- Semaglutide (Wegovy®): A GLP-1-only medication that’s slightly more affordable and available in oral and injectable forms. Supports 10–15% weight loss and cardiovascular benefits.
Quick Comparison
| Feature | Tirzepatide (Zepbound™) | Semaglutide (Wegovy®) |
|---|---|---|
| Mechanism | GLP-1 + GIP dual action | GLP-1 only |
| Weight Loss | 15–22% | 10–15% |
| HbA1c Reduction | 2.0–2.4% | 1.5–1.8% |
| Form | Injectable only | Oral or injectable |
| Side Effects | Fewer GI issues | More frequent GI issues |
| Cost (Monthly) | $1,143 | $1,417 |
Both medications are effective, but the choice depends on your health goals, preferences, and insurance coverage. Consult your doctor to determine the best fit for you.
How Does Zepbound Compare to Wegovy?
How These Medications Work
Understanding how each medication functions helps explain their different clinical effects.
Semaglutide's Effects on the Body
Semaglutide is a GLP-1 receptor agonist, with a structure that is 94% similar to human GLP-1. It works by activating receptors in the gastrointestinal tract, pancreas, and brain. This leads to slower gastric emptying, increased insulin secretion in response to glucose, and reduced glucagon release. Professor Patrick Sweeney from the University of Illinois Urbana-Champaign notes:
"When you administer semaglutide to an individual with severe obesity, it curbs their appetite, and they essentially don't feel the need to eat as drastically. It also reduces cravings for highly palatable foods. It's been very effective at reducing body weight."
Its design includes modifications to improve bioavailability (89% when injected subcutaneously) and promote albumin binding, which prevents rapid breakdown and extends its activity.
Tirzepatide's Dual Action System
Tirzepatide takes a different approach by targeting both GLP-1 and GIP receptors, unlike semaglutide, which focuses only on GLP-1. This dual-action mechanism is achieved through its 39–amino acid structure, which binds effectively to GIP receptors and has a lower affinity - about five times less - for GLP-1 receptors compared to the natural hormone. This dual targeting enhances its effects on metabolism and appetite regulation.
Main Differences in How They Work
The key difference between these drugs lies in their mechanisms of action. Here's a quick comparison:
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Primary Mechanism | GLP-1 receptor agonist | Dual agonist (GLP-1 + GIP receptors) |
| Blood Sugar Impact | A1c reduction of 1.5–1.8% | A1c reduction of 2.0–2.4% |
| Body Weight Reduction | 10–15% reduction | 15–22% reduction |
| Insulin Response | Enhances insulin secretion | Improves insulin sensitivity |
While both medications influence the hypothalamus to regulate hunger and create a negative energy balance, clinical trials show that tirzepatide leads to greater improvements in blood sugar control and weight loss compared to semaglutide. Both drugs slow gastric emptying and reduce glucose production in the liver. However, tirzepatide's activation of GIP receptors adds another layer of metabolic benefits, including increased energy expenditure, which contributes to its superior weight loss effects.
Weight Loss Results and Studies
Semaglutide Study Results
Clinical trials for Wegovy® (semaglutide) have shown promising weight loss outcomes. In placebo-controlled studies, a weekly 2.4 mg dose of semaglutide helped 73% of individuals with type 2 diabetes and 92% of those without diabetes lose at least 5% of their body weight over 68 weeks.
Tirzepatide Study Results
Tirzepatide has also delivered impressive results in clinical studies. The SURMOUNT-1 trial highlighted its impact on patients with and without type 2 diabetes. Among participants without diabetes, tirzepatide led to up to 20.9% total body weight reduction in 72 weeks, compared to just 3.1% with placebo. Additionally, 82% of participants with type 2 diabetes and 96% of those without diabetes achieved at least 5% weight loss. These results have paved the way for direct comparisons between the two medications.
"We are thrilled that today's findings showed the superior weight loss of Zepbound, which helped patients achieve 47% more relative weight loss compared to Wegovy. Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and it's changing how millions of people manage this chronic disease."
– Leonard C. Glass, MD, FACE, senior vice president of Global Medical Affairs at Lilly Cardiometabolic Health
Direct Comparison of Results
The SURMOUNT-5 trial directly compared tirzepatide (Zepbound) and semaglutide (Wegovy), involving 751 participants across the U.S. and Puerto Rico. The findings revealed clear differences in effectiveness:
| Measurement | Zepbound (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Average Weight Loss | 20.2% | 13.7% |
| Absolute Weight Loss | 50.3 lbs (22.8 kg) | 33.1 lbs (15.0 kg) |
| Patients Achieving ≥25% Loss | 31.6% | 16.1% |
These results highlight tirzepatide's stronger impact on weight management. Patricia Rodriguez, PhD, MPH, principal applied scientist at Truveta, further emphasized:
"Patients on tirzepatide were twice as likely to experience 10% weight loss and three times more likely to experience 15% weight loss within a year, compared to patients on semaglutide."
The SURPASS-2 trial also confirmed that a 15 mg dose of tirzepatide resulted in an additional 6.6% reduction in body weight compared to semaglutide.
sbb-itb-e032ee7
Side Effects and Safety
Expected Side Effects
Semaglutide (Wegovy®) and Tirzepatide (Zepbound™) often cause gastrointestinal issues as the body adjusts to the medication. These side effects are usually mild to moderate but can sometimes interfere with daily life.
Here’s a breakdown of common side effects for each medication:
| Side Effect Category | Semaglutide (Wegovy®) | Tirzepatide (Zepbound™) |
|---|---|---|
| Gastrointestinal Issues | Nausea, vomiting, diarrhea, constipation, stomach pain, decreased appetite | Nausea, vomiting, diarrhea, constipation, abdominal pain, burping, indigestion, acid reflux |
| Other Common Effects | Injection site reactions | Hair loss, fatigue, and injection site or hypersensitivity reactions |
Patient reviews back up these findings, with high satisfaction reported for Zepbound™, Mounjaro®, and Ozempic®.
Serious Risk Factors
Both medications come with important safety warnings about potential risks.
- Thyroid Tumors: Both carry boxed warnings for the risk of thyroid C-cell tumors.
- Pancreatitis: Severe abdominal pain could signal inflammation of the pancreas.
- Kidney Injury: Gastrointestinal side effects like dehydration may lead to acute kidney problems.
- Gallbladder Disease: There’s a possible link to gallbladder issues.
For diabetic patients, tirzepatide’s rapid glucose-lowering effects could worsen retinopathy.
Who Should Not Take These Medications
These medications are not suitable for everyone. They are contraindicated for individuals with:
- A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known allergies to the medication or its ingredients.
- Severe gastrointestinal diseases, including severe gastroparesis, for tirzepatide.
Use with caution if you have:
- A history of pancreatitis
- Diabetic retinopathy requiring urgent treatment
- Severe stomach emptying issues
- Upcoming surgery involving anesthesia
- A history of depression or suicidal thoughts
Blood glucose levels should be closely monitored when starting treatment.
How to Choose Between Medications
Once you've established that both medications are effective and safe, the next step is weighing practical factors to make the best choice.
How They're Taken
Semaglutide comes in two forms: an injectable (Wegovy®) and an oral tablet (Rybelsus®). Tirzepatide (Zepbound™), on the other hand, is only available as an injection. Typically, the injectable versions are taken weekly, but dosing schedules and adjustment periods can vary. Always follow your healthcare provider's instructions when starting or modifying your treatment.
Cost and Insurance Considerations
Cost and insurance coverage often play a big role in deciding between medications.
As of March 2024, here are the estimated monthly costs:
- Tirzepatide (Zepbound™): $1,143
- Semaglutide (Wegovy®): $1,417
- Semaglutide (Ozempic®): $1,050
Both Eli Lilly and Novo Nordisk offer discount programs, which can help reduce out-of-pocket costs. However, Medicare does not currently cover weight loss medications, and coverage through commercial insurance can vary widely.
"Clinically, if possible, then tirzepatide would be the preferred medication for weight loss... However, getting these medications covered by insurance is a challenge and appears worse for tirzepatide. Additionally, tirzepatide is more expensive."
– Mir Ali, MD, Board-Certified Bariatric Surgeon
When deciding, balance the cost and how the medication fits into your lifestyle and health needs.
Which Option Might Be Best for You?
The right choice depends on your personal health profile and goals. Here are some factors to consider:
Tirzepatide may be a better option if you:
- Are aiming for substantial weight loss (15–22% reduction possible)
- Have type 2 diabetes and need better glucose control
- Have experienced severe nausea or vomiting with semaglutide
- Suffer from obstructive sleep apnea
Semaglutide might be more suitable if you:
- Prefer the convenience of an oral medication
- Have cardiovascular risk factors, as semaglutide has shown benefits in this area
- Are looking for a slightly more affordable option (about 5% less expensive)
- Have better insurance coverage for semaglutide
Your healthcare provider will help you weigh these factors, taking into account your health history, insurance, and weight management goals. This personalized approach ensures the medication aligns with your specific needs.
Making Your Decision
Main Differences Summary
Here’s a quick comparison: Tirzepatide (Mounjaro®) works as a dual GLP-1 and GIP receptor agonist, while Semaglutide (Wegovy®, Ozempic®) targets only GLP-1 receptors. Clinical trials show tirzepatide leads to greater weight loss, with participants shedding 15–22% of their body weight, compared to 10–15% with semaglutide.
Comparison Overview:
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP | GLP-1 only |
| Weight Loss Impact | Higher | Moderate to high |
| HbA1c Reduction | 2.0–2.4% | 1.5–1.8% |
| Administration | Injectable only | Injectable or oral |
| GI Side Effects | Fewer | More frequent |
Use this table to guide your decision-making process.
Steps to Make Your Choice
Once you’ve reviewed the differences, follow these steps to decide which medication suits you best:
- Define Your Goals: Are you aiming for more weight loss or improved blood sugar control?
- Think About Administration: Would you prefer a once-weekly injection or an oral option?
- Check Your Insurance: Look into your coverage and compare potential out-of-pocket expenses.
- Review Your Medical History: Consider pre-existing conditions that might affect your choice.
Keep the comparison chart handy as you weigh your priorities and discuss options with your healthcare provider.
"The first steps in trying to get these medications for weight loss is for a person to see their primary care doctor. Their doctor can determine which medication is appropriate for them, what are the risks versus benefits, and if they meet insurance criteria. They may also contact their insurance company directly to ascertain coverage and benefits."
- Mir Ali, MD, Board-Certified Bariatric Surgeon and Medical Director of MemorialCare Surgical Weight Loss Center
What's Next in Weight Loss Medicine
The field of weight loss treatments is evolving fast. From 2020 to 2022, prescriptions for anti-obesity medications skyrocketed by 300%. By Q2 2023, sales hit $1.1 billion - up 65% from the previous quarter.
Pharmaceutical giants like Eli Lilly and Novo Nordisk are working on new advancements. Future medications are expected to deliver better results, fewer side effects, easier dosing options, and broader availability.
"Patients on tirzepatide were over two times more likely to experience 10% weight loss and three times more likely to experience 15% weight loss within a year, compared to patients on semaglutide. Our study also found that, in general, patients without type 2 diabetes experienced greater weight loss than patients with type 2 diabetes, but tirzepatide was more effective than semaglutide in both groups."